Clinical trial
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
NCT03906331
Study timeline
Registry last updated2025-01-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non Small Cell Lung Cancerunresolved
Medullary Thyroid Cancerunresolved
Colon Cancerunresolved
Breast Cancerunresolved
Pancreatic Cancerunresolved
Papillary Thyroid Cancerunresolved
Interventions
SelpercatinibDRUG · verified · RxNorm: selpercatinib
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
HoustonTexas, United States2BostonMassachusetts, United States2PhiladelphiaPennsylvania, United States2New YorkNew York, United States1ChicagoIllinois, United States1Los AngelesCalifornia, United States1AtlantaGeorgia, United States1San FranciscoCalifornia, United States1MadridSpain1ClevelandOhio, United States1San DiegoCalifornia, United States1ColumbusOhio, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03906331 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.